Creating Social Value

We believe our business success is interconnected with industry growth and social progress. We work to enable our clients, support employee growth, and invest in communities to drive positive impact across our value chain and create social value along with our stakeholders.

Our targets

Ensure that 80% of targeted suppliers obtain an environmental certification by 2030
Ensure that 100% of targeted suppliers sign the Supplier Code of Conduct by 2028
Ensure annual ESG assessments for 80% of targeted suppliers by 2028
Ensure annual ESG assessments for 85% of targeted suppliers by 2030

Our initiatives

Follow PSCI requirements for ethics, human rights, health and safety, environment, and management systems in our operations and supply chain
Perform environment, labor and rights assessments and on-site ESG audits on targeted suppliers, and require suppliers to sign contracts that include ESG clauses
Conduct conflict mineral and information due diligence on suppliers to ensure responsible business practices in supply chain
Maintain regular ESG performance communication with suppliers to empower supplier improvement
Provide ESG training for buyers and incorporate sustainable procurement metrics into their performance reviews
Implement supplier diversity programs to work with women or minority-owned businesses

Performance highlights

100% targeted suppliers have signed the Supplier Code of Conduct
100% of targeted suppliers have participated in ESG risk assessments
10 on-site ESG audits
82% of suppliers have signed contracts with ESG clauses
100% of buyers have been trained on sustainable procurement

Our initiatives

Optimize quality management systems across all business units, and establish food safety management systems aligned with FSSC 2000 standards for life science services and products and enzyme products
Conduct stability testing and improve the internal quality testing system
Perform regular quality audits across all business units, and engage in external quality audits to obtain international quality certifications
Implement quality supervision, training and improvement programs for suppliers through desktop, on-site, and remote audits
Regularly organize quality training for all employees, covering quality and safety awareness, quality management and manufacturing expertise, specialized training for key projects, as well as third-party training
Optimize our customer complaint tracking system to improve complaint handling efficiency, with an overall satisfaction score of 93.67%

Business Units

Quality Certification

Life Science Services and Products

ISO 9001 Quality Management System
ISO 13485 Medical Devices Quality Management System
FSSC 22000
American Halal Foundation (AHF)
European Federation for Cosmetic Ingredients (EFfCI) GMP Certification

Biologics CDMO

ISO 9001 Quality Management System
EU Qualified Person (QP)
Passed the pre-approval inspection (PAI) by the Indonesia BPOM
Drug Manufacturing Certificate issued by Jiangsu Medical Products Administration

Industrial Synthetic Biology Products

ISO 22000 Food Safety Management System
ISO 9001 Quality Management System
FSSC 22000
Feed Additives and PreMixtures Quality System
Kosher Certification
Halal Certification

Our targets

Zero child labor, forced labor or other illegal employment issues
100% of employees trained on anti-discrimination and anti-harassment
Individual development plans covering 100% of employees
Regular occupational health and safety inspections and training covering 100% of our operational sites

Our initiatives

Maintain a global talent pool through campus recruitment, employee referral program, and internal mobility program
Adopt a zero-tolerance approach to discrimination, harassment, forced labor, and child labor, and provide multiple reporting channels
Offer diverse training and development opportunities and competitive variable compensation
Improve talent review processes and promote talent mobility to establish a robust succession pipeline
Enhance employee engagement through diverse cultural events and effective employee communication channels
Identify and mitigate potential hazards through regular audits, risk assessments, and employee training

Performance highlights

100% employees with professional training
48% women in managerial positions
43% women in STEM-related positions
31 average training hours
90.2% employee satisfaction

Named a BioSpace 2025 Best Place to Work

By continuously investing in R&D, process improvement and innovative service and product offerings, we work to bring environmental and social benefits for our clients and business partners.

R&D spending of about US$54 million, up by 2.1% YoY
8.8% of our workforce dedicated to R&D
53 new patents granted
Cumulatively 254 patents granted

Environmental benefits

We proactively explore the potential of energy conservation and carbon reduction in our corporate management. We have upgraded manufacturing processes across our business units, resulting in higher R&D efficiency and reduction in energy consumption and resource waste.

Life Science Services and Products

We upgraded our NGS high-throughput detection platform for internal quality control, reducing sequencing time by 50% and increasing the capacity by 50%, with a 99% success rate. The upgrade reduced ethanol use by 80%, saving 850 L of reagents annually, and reduced tip usage by 15%, further lowering hazardous waste.
Our novel therapeutic material platform optimized large-scale production of GenExact™ ssDNA, and shortened upstream production time from 6 to 4 days, saving 64 man-hours per batch. This increased facility utilization by 50% and reduced energy consumption by 73,577 kWh per unit output.
Through process optimization, we implemented a biological approach instead traditional chromatography to reduce dsRNA generation in mRNA production, which reduced energy consumption by 50% and decreased resource usage.

Biologics CDMO Platform

Our single-use bioreactors eliminate the need for cleaning and sterilization, reducing energy consumption by 49% and water usage by 70% compared to traditional stainless-steel systems.
Through process optimization, improved material efficiency, and proactive pretreatment strategies, our protein and antibody production line reduced potential hazardous waste, achieving a 15% year-on-year reduction in 2024.

Industrial Synthetic Biology Products

Laundry protease PuriWise^® LPP
- Delivers eight-fold stain removal efficacy compared to standard detergents, achieving the same cleaning effectiveness with just one-tenth of the dosage;
- Significantly reduces overall detergent usage and lowers phosphorus emissions into water;
- Reduces energy consumption and carbon emissions during washing due to its lower operating temperature.
Sustainable feed enzyme solutions
- A new type of xylanase applied in animal feed enhances disease resistance and reduces pollution caused by animal excrement.
- By upgrading the xylanase strain and production process, the fermentation yield has increased by more than 300%, methanol usage has decreased by over 2,000 tons annually, and waste emissions have been reduced by over 60%.
- EnerGen Supreme increases the digestibility of carbohydrates in livestock and poultry by 3-5%, improving nutrient absorption.
- ProMax protease reduces crude protein levels in livestock and poultry feed by 0.5-1%, saving approximately 20 kg of soybean meal per ton of feed and reducing nitrogen emissions by 5-10%.
- Phytase reduces the need for dicalcium phosphate in feed formulation, saving 6-10 kg per ton and lowering phosphorus emissions.

Social benefits

GenScript launched the FLASH Gene service, an ultra-fast sequence-to-plasmid solution that offers the fastest turnaround time in the industry at just four business days. This advancement is poised to significantly accelerate research and discovery efforts in the development of antibody drugs, vaccines, and CGT.
GenScript’s proprietary TurboCHO™ platform leads the industry turnaround time — just 5 business days from gene to antibody. With a large capacity of over 30,000 targets per month, TurboCHO™ ensures seamless production with scalable production up to gram level, accelerating scientific research and new drug development.
With DMF authorization from the U.S. FDA, we supported Base Therapeutics Co., Ltd. in developing the world’s first base-edited universal NK cell product for the treatment of advanced solid tumors, which received IND approvals from the U.S. FDA and the NMPA.
Our subsidiary ProBio launched ProSyn™ cell-free linearlized DNA platform, enabling GMP linearized plasmid production in shorter turnround time. This innovation will facilitate scalable production of cell and gene therapies (CGT) and personalized cancer vaccines, underscoring our dedication to advancing accessible, next-generation healthcare solutions.
GenScript’s subsidiary ProBio licensed its anti-PD-1 NME to LaNova Medicines, enabling the development of the PD-1/VEGF bispecific antibody LM-299. Merck’s partnership with LaNova further validates the potential of this innovative approach. Our anti-PD-1 single-domain antibody is a key next-generation cancer treatment.

GenScript’s ongoing efforts to give back through charitable initiatives, community outreach, and industry engagement are central to our mission. We are committed to creating a positive change and fostering a sustainable future for all.

Industry Engagement